U.S. Research Hospital Embraces AI-driven Prostate Cancer Management with Avenda Health’s Unfold AI™

Avenda Health's Unfold AI™ platform changing the face of personalized prostate cancer care

Unfold AI™ platform by Avenda Health: A breakthrough in personalized prostate cancer care using AI technology

At a leading U.S. research hospital, patients are now benefiting from Avenda Health’s Unfold AI™, an FDA cleared platform revolutionizing prostate cancer management. The AI-powered platform is designed to assist physicians and patients in treatment selection, planning, guidance, and follow-up, thus enhancing the quality of care and improving outcomes.

Physicians at the research hospital, including Wayne Brisbane, MD, are already using the technology in their practice. In clinical studies, the platform has increased urologists’ tumor identification sensitivity to over 98% by analyzing data from prostate imaging, biopsies, and pathology using deep-learning algorithms. This impressive technology generates a unique 3D map of the cancer location, helping physicians make better-informed treatment decisions and plan interventions more effectively.

Dr. Leonard Marks, co-founder and Chief Medical Officer of Avenda Health, stated, “Our mission at Avenda Health is to create a better quality of life for prostate cancer patients and to give urologists a clearer view of the cancer so we can better treat our patients. Unfold AI will improve clinical care and decision making. This is a major step forward for the prostate cancer community, and we are beyond thrilled to see a decade of hard work and research pay off.”

During clinical trials, the platform’s guidance has been instrumental in changing treatment recommendations in 28% of cases, often opting for more localized treatment. Unfold AI allows for various treatment options, such as active surveillance, whole gland treatments like radical prostatectomy and radiation therapy, or Avenda Health’s FocalPoint soft tissue laser ablation device.

Avenda Health is dedicated to bringing its cutting-edge technology to all practices and physicians treating prostate cancer patients, aiming to establish a new standard of cancer care. The company is committed to ensuring the platform revolutionizes the way prostate cancer is treated, improving patient outcomes, and preserving their quality of life.

The U.S. FDA granted 510(k) clearance to Unfold AI in December 2022. To learn more about Avenda Health and its pioneering platform, visit avendahealth.com.


Leave a Reply

Your email address will not be published.